Malignant Hyperthermia
9
1
1
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
11.1%
1 terminated out of 9 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
The Prevalence of RYR1-related Disease
A Case Control Study of Patients With Diagnosis of Malignant Hyperthermia
Screening of Malignant Hyperthermia Susceptible Individuals
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia
Gene Mutation Spectrum of Malignant Hyperthermia in China
Multisystem Features of Malignant Hyperthermia or Rhabdomyolysis Related to RYR1 Variants
Malignant Hyperthermia Registry and Genetic Testing
Spanish Registry of RYR1 and CACNA1S Polymorphisms
Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient